Ocugen develops gene therapies aimed at treating inherited retinal diseases and other conditions that cause vision loss. OCGN reports earnings on Wed, Nov 4, 2026.
Prices, price targets and earnings estimates for OCGN are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in OCGN in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OCGN is in one of them and how their past OCGN trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Ocugen
Ocugen is a company based in Malvern, Pennsylvania, that develops gene therapies for eye diseases. Its work centers on modifier gene therapies intended to treat inherited retinal diseases such as retinitis pigmentosa and Stargardt disease, as well as geographic atrophy, an advanced form of macular degeneration. The candidates are designed to be given as a single injection beneath the retina, with the aim of slowing vision loss in patients. The therapies are still in clinical development and are not yet approved for sale.
